Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 17/20 | 0.80 |
| ▸ | KDR | P35968 | 12/20 | 0.80 |
| ▸ | SRC | P12931 | 4/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.63 |
| ▸ | CASK | O14936 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.63 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586865 | 1.00 | RET (0.80) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12422335 | 0.90 | RET (0.81) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL30071468 | 0.89 | RET (1.00) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL19476374 | 0.89 | RET (1.00) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL30071121 | 0.88 | RET (0.62) | RETKDR | |
| SCHEMBL19477015 | 0.88 | RET (0.62) | RETKDR | |
| SCHEMBL29586659 | 0.85 | RET (0.81) | RETKDR | |
| SCHEMBL30071273 | 0.85 | RET (0.80) | RETKDRPIK3CDPRKDC | |
| SCHEMBL19477016 | 0.85 | RET (0.80) | RETKDRPIK3CDPRKDC | |
| SCHEMBL19476281 | 0.85 | RET (0.80) | RETKDRSRCABL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| CN-109195972-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| WO-2017178844-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885SRC 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.